FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Cher

Research Profile

Disorders

Living Beings

Chemicals & Drugs

Anatomy

Procedures

Physiology

Cell Divisions

Concepts & Ideas

Co-author Network

Publications

TOP 3
Wei Huang; Allen Saliganan; Carolyn Ustach; Christoph Wiesner; R Daniel Bonfil; Michael L Cher; M K Conley-LaComb; Y Fridman; H-R C Kim
A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth.
Abdo J Najy; Allen Saliganan; Joshua J Won; R Daniel Bonfil; Michael L Cher; M Katie Conley-LaComb; Elisabeth Iljas Heath; Young Suk Jung; Chong Jai Kim; Hyeong-Reh Choi Kim
Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.
M Katie Conley-LaComb; Rafael Fridman; Wei Huang; Young Suk Jung; R Daniel Bonfil; Yong Q Chen; Michael L Cher; Abdo Najy; Dongping Shi; Shihua Wang; Hyeong-Reh Choi Kim
PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Cher (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Wei Huang; Allen Saliganan; Carolyn Ustach; Christoph Wiesner; R Daniel Bonfil; Michael L Cher; M K Conley-LaComb; Y Fridman; H-R C Kim
A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth.
Oncogene 2012;31(42):4527-35.
2012: Abdo J Najy; Allen Saliganan; Joshua J Won; R Daniel Bonfil; Michael L Cher; M Katie Conley-LaComb; Elisabeth Iljas Heath; Young Suk Jung; Chong Jai Kim; Hyeong-Reh Choi Kim
Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.
The Prostate 2012;72(12):1328-38.
2012: M Katie Conley-LaComb; Rafael Fridman; Wei Huang; Young Suk Jung; R Daniel Bonfil; Yong Q Chen; Michael L Cher; Abdo Najy; Dongping Shi; Shihua Wang; Hyeong-Reh Choi Kim
PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer.
The American journal of pathology 2012;180(3):1017-27.
2012: Dejuan Kong; Yiwei Li; Mani Menon; Isaac J Powell; Wael A Sakr; Seema Sethi; Shadan Ali; Wei Chen; Michael L Cher; Dhananjay Chitale; Nilesh Gupta; Oudai Hassan; Elisabeth Iljas Heath; Lance K Heilbrun; Clara Hwang; Asfar S Azmi
Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM.
PloS one 2012;7(3):e33729.
2012: Dejuan Kong; Yiwei Li; Mani Menon; Isaac J Powell; Wael A Sakr; Seema Sethi; Shadan Ali; Wei Chen; Michael L Cher; Dhananjay Chitale; Nilesh Gupta; Oudai Hassan; Elisabeth Iljas Heath; Lance K Heilbrun; Clara Hwang; Asfar S Azmi
Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.
American journal of translational research 2012;4(1):14-23.
2011: Maria Margarida Bernardo; R Daniel Bonfil; Michael L Cher; Ivory Dean; Alan Anthony Dombkowski; Gregory Dyson; Sijana Dzinic; Alexander Kaplun; David Krass; Xiaohua Li; Jaron Lockett; Yonghong Meng; Kamiar Moin; Mary Olive; Wael A Sakr; Shuping Yin; Shijie Sheng
Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation.
Genes & cancer 2011;2(11):1009-22.
2011: Nivedita Bhatta Dhar; Michael L Cher; John F Ward; J Stephen Jones
Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry.
BJU international 2011;108(4):508-12.
2011: Xiaoning Zhe; Michael L Cher; R Daniel Bonfil
Circulating tumor cells: finding the needle in the haystack.
American journal of cancer research 2011;1(6):740-51.
2010: Aaron L Sabbota; Hyeong-Reh Choi Kim; Xiaoning Zhe; Rafael Fridman; R Daniel Bonfil; Michael L Cher
Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration.
Cancer research 2010;70(13):5558-66.
2010: Iftekhar U Ahmad; Jeffrey D Forman; Asfar S Azmi; Gilda G Hillman; Elisabeth Iljas Heath; Ulka Nitin Vaishampayan; Michael L Cher; Fundagul Andic; Peter J Rossi; Omer Kucuk
Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer.
Nutrition and cancer 2010;62(7):996-1000.
2010: Juan Cai; Pridvi Kandagatla; Rajareddy Singareddy; Anthony Kropinski; Shijie Sheng; Michael L Cher; Sreenivasa R Chinni
Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells.
Translational oncology 2010;3(3):195-203.
2009: Ulka Nitin Vaishampayan; SHANTHI MARUR; Lance K Heilbrun; Michael L Cher; Brenda Dickow; Daryn W Smith; Samir A Al Hasan; James Eliason
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
The Journal of urology 2009;182(1):317-23.
2008: Christoph Wiesner; Sanaa M Nabha; Emanuel Burck Dos Santos; Hamilto Yamamoto; Hong Meng; Sebastian W Melchior; Fernando Bittinger; Joachim W Thüroff; Robert L Vessella; Michael L Cher; R Daniel Bonfil
C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis.
Neoplasia (New York, N.Y.) 2008;10(9):996-1003.
2008: R Daniel Bonfil; Rafael Fridman; Shahriar Mobashery; Michael L Cher
Are matrix metalloproteinases relevant therapeutic targets for prostate cancer bone metastasis?
Current oncology (Toronto, Ont.) 2008;15(4):188-92.
2008: Dejuan Kong; Zhiwei Wang; Sarah H Sarkar; Yiwei Li; Sanjeev Banerjee; Allen Saliganan; Hyeong-Reh Choi Kim; Michael L Cher; Asfar S Azmi
Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells.
Stem cells (Dayton, Ohio) 2008;26(6):1425-35.
2008: Sanaa M Nabha; Emanuel Burck dos Santos; Hamilto A Yamamoto; Abdelfettah Belizi; Zhong Dong; Hong Meng; Allen Saliganan; Aaron Sabbota; R Daniel Bonfil; Michael L Cher
Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner.
International journal of cancer. Journal international du cancer 2008;122(11):2482-90.
2008: Zhong Dong; Allen D Saliganan; Hong Meng; Sanaa M Nabha; Aaron L Sabbota; Shijie Sheng; R Daniel Bonfil; Michael L Cher
Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.
Neoplasia (New York, N.Y.) 2008;10(5):439-49.
2008: Sreenivasa R Chinni; Hamilto Yamamoto; Zhong Dong; Aaron Sabbota; R Daniel Bonfil; Michael L Cher
CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.
Molecular cancer research : MCR 2008;6(3):446-57.
2007: R Daniel Bonfil; Sreenivasa R Chinni; Rafael Fridman; Hyeong-Reh Choi Kim; Michael L Cher
Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis.
Urologic oncology 2007;25(5):407-11.
2007: R Daniel Bonfil; Zhong Dong; J Carlos Trindade Filho; Aaron Sabbota; Pamela Osenkowski; Sanaa M Nabha; Hamilto Yamamoto; Sreenivasa R Chinni; Huiren Zhao; Shahriar Mobashery; Robert L Vessella; Rafael Fridman; Michael L Cher
Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth.
The American journal of pathology 2007;170(6):2100-11.
2007: Sanjeev Banerjee; Maha Hussain; Zhiwei Wang; Allen Saliganan; Mingxin Che; R Daniel Bonfil; Michael L Cher; Asfar S Azmi
In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer.
Cancer research 2007;67(8):3818-26.
2007: Christoph Wiesner; R Daniel Bonfil; Zhong Dong; Hamilto Yamamoto; Sanaa M Nabha; Hong Meng; Allen Saliganan; Aaron Sabbota; Michael L Cher
Heterogeneous activation of MMP-9 due to prostate cancer-bone interaction.
Urology 2007;69(4):795-9.
2007: Ulka Nitin Vaishampayan; Maha Hussain; Mousumi Banerjee; Soley Seren; Asfar S Azmi; Joseph A Fontana; Jeffrey D Forman; Michael L Cher; Isaac J Powell; J Edson Pontes; Omer Kucuk
Lycopene and soy isoflavones in the treatment of prostate cancer.
Nutrition and cancer 2007;59(1):1-7.
2007: Hamilto Yamamoto; R Daniel Bonfil; Christoph Wiesner; Sanaa M Nabha; Zhong Dong; Hong Meng; Allen Saliganan; Aaron Sabbota; Sreenivasa R Chinni; Michael L Cher
Quantitative assessment of small intraosseous prostate cancer burden in SCID mice using fluorescence imaging.
The Prostate 2007;67(1):107-14.
2006: Xiyun Deng; Sunita Bhagat; Zhong Dong; Chadwick Mullins; Sreenivasa R Chinni; Michael L Cher
Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel.
European journal of cancer (Oxford, England : 1990) 2006;42(18):3267-73.
2006: R Daniel Bonfil; Aaron Sabbota; Sanaa M Nabha; Maria Margarida Bernardo; Zhong Dong; Hong Meng; Hamilto Yamamoto; Sreenivasa R Chinni; In Taek Lim; Mayland Chang; Lusia C Filetti; Shahriar Mobashery; Michael L Cher; Rafael Fridman
Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor.
International journal of cancer. Journal international du cancer 2006;118(11):2721-6.
2006: Michael L Cher; Dwight A Towler; Shahin Rafii; David Rowley; Henry J Donahue; Evan T Keller; Meenhard Herlyn; Eun Ah Cho; Leland W K Chung
Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section.
The American journal of pathology 2006;168(5):1405-12.
2006: Yiwei Li; Omer Kucuk; Maha Hussain; Judith Abrams; Michael L Cher; Asfar S Azmi
Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
Cancer research 2006;66(9):4816-25.
2006: Shuping Yin; Jaron Lockett; Yonghong Meng; Hector Biliran; GRant Blouse; Xiaohua Li; Neelima Reddy; Zimin Zhao; Xinli Lin; John Anagli; Michael L Cher; Shijie Sheng
Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Cancer research 2006;66(8):4173-81.
2006: Sanaa M Nabha; R Daniel Bonfil; Hamilto A Yamamoto; Abdelfettah Belizi; Christoph Wiesner; Zhong Dong; Michael L Cher
Host matrix metalloproteinase-9 contributes to tumor vascularization without affecting tumor growth in a model of prostate cancer bone metastasis.
Clinical & experimental metastasis 2006;23(7-8):335-44.
2006: Sreenivasa R Chinni; Sivasakthy Sivalogan; Zhong Dong; J Carlos Trindade Filho; Xiyun Deng; R Daniel Bonfil; Michael L Cher
CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.
The Prostate 2006;66(1):32-48.
2005: Gaëlle Fromont; Antoine Valeri; Michael L Cher; J Edson Pontes; Guy Vallancien; Pierre Validire; Alain Latil; Olivier Cussenot
Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer.
The Prostate 2005;65(4):341-6.
2005: Zhong Dong; R Daniel Bonfil; Sreenivasa R Chinni; Xiyun Deng; J Carlos Trindade Filho; Maria Margarida Bernardo; Ulka Nitin Vaishampayan; Mingxin Che; Bonnie F Sloane; Shijie Sheng; Rafael Fridman; Michael L Cher
Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue.
The American journal of pathology 2005;166(4):1173-86.
2005: Bonnie F Sloane; Shiqing Yan; Izabela Podgorski; Bruce E Linebaugh; Michael L Cher; Jianxin Mai; Dora Cavallo-Medved; Mansoureh Sameni; Julie Dosescu; Kamiar Moin
Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment.
Seminars in cancer biology 2005;15(2):149-57.
2005: Antoine Valeri; Gaëlle Fromont; Wael A Sakr; Rahmène Azzouzi; Jyotirmoy Dey; Karine Chantrel-Groussard; Alain Latil; Philippe Berthon; Olivier Cussenot; J Edson Pontes; Michael L Cher
High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy.
Urologic oncology 2005;23(2):87-92.
2005: Izabela Podgorski; Bruce E Linebaugh; Mansoureh Sameni; Christopher Jedeszko; Sunita Bhagat; Michael L Cher; Bonnie F Sloane
Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer.
Neoplasia (New York, N.Y.) 2005;7(3):207-23.
2004: Yiwei Li; Mingxin Che; Sunita Bhagat; Kerrie-Lynn Ellis; Omer Kucuk; Daniel R Doerge; Judith Abrams; Michael L Cher; Asfar S Azmi
Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein.
Neoplasia (New York, N.Y.) 2004;6(4):354-63.
2004: Carolyn V Ustach; Marcus E Taube; Newton J Hurst; Sunita Bhagat; R Daniel Bonfil; Michael L Cher; Lucia Schuger; Hyeong-Reh Choi Kim
A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression.
Cancer research 2004;64(5):1722-9.
2004: Rosa G Rotenberg; Natalia S Rozas; Lucia GUERRI; Michael L Cher; Mercedes Gamboni; Nancy Lema; R Daniel Bonfil
Elevated levels of angiostatin in effusions from patients with malignant disease.
Oncology reports 2004;11(2):523-8.
2004: O Graciela Scharovsky; Maria Mercedes Binda; Viviana R Rozados; Sunita Bhagat; Michael L Cher; R Daniel Bonfil
Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance.
Clinical & experimental metastasis 2004;21(2):177-83.
2004: R Daniel Bonfil; Pamela Osenkowski; Rafael Fridman; Michael L Cher
Matrix metalloproteinaes and bone metastasis.
Cancer treatment and research 2004;118():173-95.
2003: Michael L Cher; Hector Biliran; Sunita Bhagat; Yonghong Meng; Mingxin Che; Jaron Lockett; Judith Abrams; Rafael Fridman; Michael Zachareas; Shijie Sheng
Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(13):7847-52.
2003: Fernando J Bianco; David P Wood Jr; Michael L Cher; Isaac J Powell; Julia W Souza; J Edson Pontes
Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer.
Clinical prostate cancer 2003;1(4):242-7.
2003: Suresh Mohla; Katherine N Weilbacher; Michael L Cher; Babatunde Oyajobi; Catherine Van Poznak; Dennis R Clohisy
Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessions.
Cancer 2003;97(3 Suppl):719-25.
2003: Daotai Nie; Jeffrey A Nemeth; Yan Qiao; Alex Zacharek; Li Li; Kenny Hanna; Keqin Tang; Gilda G Hillman; Michael L Cher; David Grignon; Kenneth V Honn
Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase.
Clinical & experimental metastasis 2003;20(7):657-63.
2003: Jeffrey A Nemeth; Michael L Cher; Zhao Zhou; Chadwick Mullins; Sunita Bhagat; Mohit Trikha
Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases.
Clinical & experimental metastasis 2003;20(5):413-20.
2002: Fernando J Bianco; Isaac J Powell; Michael L Cher; David P Wood Jr
Presence of circulating prostate cancer cells in African American males adversely affects survival.
Urologic oncology 2002;7(4):147-52.
2002: Isaac J Powell; Jyotirmoy Dey; Amanda Dudley; J Edson Pontes; Michael L Cher; Wael A Sakr; David Grignon; David P Wood Jr
Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis.
Urology 2002;59(6):907-12.
2002: Jeffrey A Nemeth; Rafid Yousif; Michael Herzog; Mingxin Che; Jyoti Upadhyay; Bijan Shekarriz; Sunita Bhagat; Chadwick Mullins; Rafael Fridman; Michael L Cher
Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
Journal of the National Cancer Institute 2002;94(1):17-25.
2002: Vivek Narain; Michael L Cher; David P Wood Jr
Prostate cancer diagnosis, staging and survival.
Cancer metastasis reviews 2002;21(1):17-27.
2001: Fernando J Bianco; David P Wood Jr; J Gomes de Oliveira; Jeffrey A Nemeth; AA Beaman; Michael L Cher
Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer.
The Prostate 2001;49(4):235-42.
2001: Michael L Cher
Mechanisms governing bone metastasis in prostate cancer.
Current opinion in urology 2001;11(5):483-8.
2001: Zhong Dong; Jeffrey A Nemeth; Michael L Cher; KC Palmer; R C Bright; Rafael Fridman
Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells.
International journal of cancer. Journal international du cancer 2001;93(4):507-15.
2000: Marta Toth; Maria Margarida Bernardo; David C Gervasi; Paul D Soloway; Zhijian Wang; Heather F Bigg; Christopher M Overall; Yves A DeClerck; H Tschesche; Michael L Cher; Stephen Brown; Shahriar Mobashery; Rafael Fridman
Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2.
The Journal of biological chemistry 2000;275(52):41415-23.
2000: Bharati Hukku; M Mally; Michael L Cher; D M Peehl; H Kung; Johng S Rhim
Stepwise genetic changes associated with progression of nontumorigenic HPV-18 immortalized human prostate cancer-derived cell line to a malignant phenotype.
Cancer genetics and cytogenetics 2000;120(2):117-26.
2000: Jeffrey A Nemeth; J W Roberts; C M Mullins; Michael L Cher
Persistence of human vascular endothelium in experimental human prostate cancer bone tumors.
Clinical & experimental metastasis 2000;18(3):231-7.
1999: Jyoti Upadhyay; Bijan Shekarriz; Jeffrey A Nemeth; Zhong Dong; G D Cummings; Rafael Fridman; Wael A Sakr; David Grignon; Michael L Cher
Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4105-10.
1999: JB Virgin; P M Hurley; Fatimah A Nahhas; K G Bebchuk; Anwar N Mohamed; Wael A Sakr; R K Bright; Michael L Cher
Isochromosome 8q formation is associated with 8p loss of heterozygosity in a prostate cancer cell line.
The Prostate 1999;41(1):49-57.
1999: Michael L Cher; JG de Oliveira; AA Beaman; Jeffrey A Nemeth; Maha Hussain; David P Wood Jr
Cellular proliferation and prevalence of micrometastatic cells in the bone marrow of patients with clinically localized prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2421-5.
1999: Jeffrey A Nemeth; JF Harb; U Barroso; Z He; David Grignon; Michael L Cher
Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Cancer research 1999;59(8):1987-93.
1999: MM Kattar; David Grignon; J N Eble; P M Hurley; P E Lewis; Wael A Sakr; Michael L Cher
Chromosomal analysis of renal angiomyolipoma by comparative genomic hybridization: evidence for clonal origin.
Human pathology 1999;30(3):295-9.
1999: Gilda G Hillman; Jeffrey A Triest; Michael L Cher; SV Kocheril; BR Talati
Prospects of immunotherapy for the treatment of prostate carcinoma--a review.
Cancer detection and prevention 1999;23(4):333-42.
1998: Michael L Cher; Fernando J Bianco; J S Lam; Lawrence Davis; David Grignon; Wael A Sakr; Mousumi Banerjee; J Edson Pontes; David P Wood Jr
Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy.
The Journal of urology 1998;160(4):1387-91.
1998: David P Wood Jr; AA Beaman; Mousumi Banerjee; Isaac J Powell; Edson J Pontes; Michael L Cher
Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(9):2119-23.
1998: Jeffrey A Triest; David Grignon; Michael L Cher; SV Kocheril; EJ Montecillo; BR Talati; Samuel Tekyi-Mensah; J Edson Pontes; Gilda G Hillman
Systemic interleukin 2 therapy for human prostate tumors in a nude mouse model.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):2009-14.
1998: P Mueller; P Carroll; E Bowers; D Moore; Michael L Cher; J Presti; M Wessman; M G Pallavicini
Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant.
Cancer 1998;83(3):538-46.
1998: EL Gheiler; MV Tefilli; Rabi Tiguert; David Grignon; Michael L Cher; Wael A Sakr; J Edson Pontes; David P Wood Jr
Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer.
Urology 1998;51(5):789-95.
1998: Michael L Cher; P E Lewis; Mousumi Banerjee; P M Hurley; Wael A Sakr; David Grignon; Isaac J Powell
A similar pattern of chromosomal alterations in prostate cancers from African-Americans and Caucasian Americans.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1273-8.
1997: Tony E Godfrey; Michael L Cher; V Chhabra; Ronald H Jensen
Allelic imbalance mapping of chromosome 16 shows two regions of common deletion in prostate adenocarcinoma.
Cancer genetics and cytogenetics 1997;98(1):36-42.
1997: JA Connolly; Joseph C Presti; Michael L Cher; Karen L Chew; Katsuto Shinohara; Peter R Carroll
Accelerated tumor proliferation rates in locally recurrent prostate cancer after radical prostatectomy.
The Journal of urology 1997;158(2):515-8.
1997: Dan H Moore; Maria G Pallavicini; Michael L Cher; Joe Gray
A t-statistic for objective interpretation of comparative genomic hybridization (CGH) profiles.
Cytometry 1997;28(3):183-90.
1996: Michael L Cher; G Steven Bova; Dan H Moore; Eric J Small; Peter R Carroll; Sokhom Pin; Jonathan I Epstein; William B Isaacs; R H Jensen
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping.
Cancer research 1996;56(13):3091-102.
1996: Timothy J Yeatman; Michael L Cher; W Mao; M Wloch; T Tedesco
Identification of genetic alterations associated with the process of human experimental colon cancer liver metastasis in the nude mouse.
Clinical & experimental metastasis 1996;14(3):246-52.
1996: Michael L Cher; R A Stephenson; Brent C James; Peter R Carroll
Cellular proliferative fraction of metastatic lymph nodes predicts survival in stage D1 (TxN+M0) prostate cancer.
The Journal of urology 1996;155(5):1674-7.
1996: Kenneth V Honn; A Aref; Yong Q Chen; Michael L Cher; JD Crissman; Jeffrey D Forman; X Gao; David Grignon; Maha Hussain; AT Porter; J Edson Pontes; Isaac J Powell; Bruce G Redman; Wael A Sakr; Richard K Severson; Ding "Dean" G. Tang; David P Wood Jr
Prostate cancer old problems and new approaches : Part I. epidemiology, incidence and genetic alterations.
Pathology oncology research : POR 1996;2(1-2):98-109.
1996: Michael L Cher; B B Abernathy; John D McConnell; Philippe E Zimmern; Victor K Lin
Smooth-muscle myosin heavy-chain isoform expression in bladder-outlet obstruction.
World journal of urology 1996;14(5):295-300.
1995: Michael L Cher; Katsuto Shinohara; S Breslin; J Vapnek; Peter R Carroll
High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
British journal of urology 1995;75(6):771-7.
1995: J. Stuart Wolf, Jr.; Michael L Cher; Marc A Dall'Era; Joseph C Presti; Hedvig Hricak; Peter R Carroll
The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy.
The Journal of urology 1995;153(3 Pt 2):993-9.
1995: Michael L Cher; Peter R Carroll
Screening for prostate cancer.
The Western journal of medicine 1995;162(3):235-42.
1995: Michael L Cher; Karen L Chew; W Rosenau; Peter R Carroll
Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression.
The Prostate 1995;26(2):87-93.
1995: Michael L Cher; T Ito; N Weidner; Peter R Carroll; R H Jensen
Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH).
The Journal of urology 1995;153(1):249-54.
1994: Michael L Cher; D MacGrogan; Robert Bookstein; James A Brown; R B Jenkins; R H Jensen
Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer.
Genes, chromosomes & cancer 1994;11(3):153-62.
1994: Michael L Cher; P R Carroll
Screening for prostate cancer.
The Western journal of medicine 1994;160(3):250.
1993: Michael L Cher; T D Allen
Continence in the myelodysplastic patient following enterocystoplasty.
The Journal of urology 1993;149(5):1103-6.
1993: Michael L Cher; Sara Milchgrub; Arthur I Sagalowsky
Transitional cell carcinoma of the ureteral stump 23 years after radical nephrectomy for adenocarcinoma.
The Journal of urology 1993;149(1):106-8.